Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
February 2020
-
Key ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelleLes actionnaires approuvent la 23e augmentation consécutive du dividende qui passe à CHF 2.95 (+4%) par action pour l’année 2019, soit un rendement de 3,5%1 et une distribution du free cash-flow…
-
Parental Leave at Novartis: Alfred’s story
At Novartis, we celebrate life and recognize moments that matter. Alfred Ambatlle shares his experience of parental leave and becoming a father of twins.
-
Media ReleaseNovartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasisLXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust Novartis is responsible for completing Phase I clinical trials and has committed to…
-
Shaping the future of sickle cell disease
Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.
-
Media ReleaseNovartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as…
-
Collaboration is strengthening care for chronic illness in Ethiopia
Working with a nonprofit, Novartis is helping train healthcare workers to diagnose and treat chronic ailments such as diabetes.
-
Media ReleaseNovartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwideBeovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on three-month dosing intervals immediately after the loading…
-
Media ReleaseNovartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA reviewFDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)1 …
-
StatementAVXS-101 Managed Access Program
-
Featured NewsWorld Cancer Day 2020
Novartis is supporting World Cancer Day by reimagining cancer in the workplace through a dedicated global program.
-
Reimagining cancer in the workplace
Novartis is strongly committed in helping and supporting employees impacted by cancer through the program Ensemble – Caring for Colleagues (Ensemble).
-
In The NewsNovartis CEO Vasant Narasimhan on building trust with societyVas Narasimhan, CEO of Novartis, and CNBC’s Meg Tirrell joins “Closing Bell” in an exclusive interview at the JPMorgan Healthcare Conference.
Pagination
- ‹ Previous page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- …
- 152
- › Next page